Kornimate/medical-research-clean huggingface dataset:
intervention for improving psychological distress in dialysis

Conditions: Kidney Failure, Chronic; Depression; Anxiety

Summary: to explore whether it is feasible to recruit and retain haemodialysis patients into a randomised controlled trial of online cognitive-behavioural therapy to manage distress


Eligibility criteria:
inclusion criteria: 1. aged 18 years or over and receive hospital haemodialysis three-times weekly 2. presence of mild to moderately severe depressive symptoms (based on phq-9 scores of 5 to 19 in range; a self-report measure of depression) and/or presence of mild to moderate anxiety symptoms (based on gad-7 scores of 5-14) 3. speak english sufficiently well to engage with screening tools 4. have a basic understanding of how to use the internet and an email address 5. have a minimum dialysis vintage of ≥3 months (electronic patient record) exclusion criteria: 1. hospitalised at the time of assessment or within 1 month prior to the assessment 2. currently receiving active treatment for depression and/or anxiety. we consider active treatment to be any current psychological treatments (talking therapies) or receipt of a new anti-depressant and/or anti-anxiety medication. a medication is considered new if it is commenced three months prior to the completion of the depression and anxiety screening questionnaire 3. severe mental health disorders, for example, psychosis, bi-polar disorder 4. active suicidal thoughts-any participant that scores greater than one on the depression phq-9 item "thoughts that you would be better off dead, or of hurting yourself" will be excluded from the study. 5. evidence of addiction to alcohol or drugs

Keywords: feasibility study randomised controlled trial cognitive behavioural therapy psychological distress cognitive illness representations common sense model
indomethacin and cardiac bypass surgery

Conditions: Hemorrhage

Summary: following signed informed consent, patients scheduled for elective cardiac surgery were randomly assigned to one of 3 groups to be given acetaminophen, indomethacin or a combination of both immediately following induction and then at 6, 12, 18 \& 24 hours following surgery. our primary outcome measure was the amount of blood drained from the mediastinal tubes and chest drains. secondary outcome measures included conventional blood coagulation indices as well as other measures of clotting as indicated by thromboelastography (teg). other secondary outcome measures included consumption of morphine equivalents and pain scores.


Eligibility criteria:
inclusion criteria: * scheduled to undergo either elective coronary artery bypass or single valve replacement * normal platelet count * normal prothrombin time * normal partial thromboplastin time * normal serum creatinine exclusion criteria: * sensitivity to study drugs * history of bleeding diathesis * renal dysfunction * active peptic ulcer

Keywords: nsaids bleeding thromboelastography cardiac surgery indomethacin acetaminophen
a study to investigate safety, tolerability, pharmacokinetics (pk), pharmacodynamics (pd), and immunogenicity of ro7669330 in participants with geographic atrophy (ga) secondary to age-related macular degeneration (amd)

Conditions: Geographic Atrophy; Age-related Macular Degeneration

Summary: the main purpose of this study is to assess the ocular and systemic safety and tolerability of ro7669330 in ga secondary to amd after multiple unilateral intravitreal (ivt) doses.


Eligibility criteria:
inclusion criteria: * adequately clear ocular media, adequate pupillary dilation, and fixation to allow acquisition of good quality fundus imaging * ga that resides completely within the fundus autofluorescence (faf) imaging field * presence of hyperautofluorescence of either banded or diffuse pattern adjacent to the ga area on faf * study eye has early treatment of diabetic retinopathy study (etdrs) best-corrected visual acuity (bcva) score as follows: * part 1a: 19 to 48 letters inclusively * part 1b: \> 19 letters * part 2: ≥ 24 letters * total ga lesion size must be as follows: * parts 1a and 1b: ≥ 1.25 square millimeter (mm\^2) and ≤ 17.5 mm\^2 ) * part 2: ≥ 2.5 mm\^2 and ≤ 17.5 mm\^2 exclusion criteria: ocular exclusion criteria for the study eye: * aphakic or pseudophakic with intraocular lens outside of the capsular bag * previous laser photocoagulation or ivt anti-vascular endothelial growth factor (vegf) for cnv, diabetic macular edema (dme), retinal vein occlusion (rvo), or proliferative diabetic retinopathy ocular exclusion criteria for the non-study eye: - non-functioning non-study eye, defined as either: bcva of hand motion or worse and/or no physical presence of eye ocular exclusion criteria for both eyes: * macular atrophy in either eye due to causes other than amd * evidence of prior or active cnv * prior treatment with any approved therapy for ga (syfovre, izervay) in either eye for part 1a and part 2. for part 1b, prior treatment with any approved therapy for ga (syfovre, izervay) in the study eye ≤ 20 weeks prior to day 1
pelvic floor study: biomechanical properties of the female pelvic floor

Conditions: Pelvic Organ Prolapse

Summary: pelvic floor dysfunction in the form of pelvic organ prolapse or urinary and fecal incontinence is a sequela for some women who experience injuries during birth. it affects adult women of all ages. the life time risk for women by age of 80 years for undergoing surgical correction is shown to be 11.1 % , and 29 % of them will undergo re-operation for recurrences later on. still, even today the biomechanics of the pelvic floor is not understood enough. the aim of our study is to investigate the biomechanical properties of the female pelvic floor, i.e. the vaginal wall, by means of clinical, sonomorphometric (ultrasound), histological and elastomechanical examinations. in principle, the elasto-mechanical properties of the vaginal wall will be examined by the new and innovative so called aspiration device, developed at the eidgenoessische technische hochschule (eth) zurich, switzerland. this tool generates a low-pressure of -25 mbar at the vaginal wall, aspirating it under visual control by aid of an integrated video camera and therefore allowing to measure the difference of its convexity under aspiration and at rest. in case of prolapse surgery, this allows us to take a biopsy of the measured vaginal wall and analyze it at the institute of anatomy at the university of zurich-irchel by means of histological (e.g. connective tissue, extracellular matrix) and molecular biological examination. with an increasing elderly population, more and more women will need surgery for pelvic organ prolapse. while effective in restoring anatomy, sometimes by aid of meshes made out of polypropylene, the functional outcomes and quality of life are not always restored satisfactorily. this interdisciplinary project intends to add a contribution to this for our patient still bothersome situation and to help to detect risk factors for developing pelvic floor dysfunction.


Eligibility criteria:
inclusion criteria: * pre- and postmenopausal women * with pelvic organ prolapse, i.e. cysto- or rectocele, uterine descensus * postmenopausal women exclusion criteria: * age under 18 years * pregnancy / lactation * current gynaecologic malignancies * current malignancies of the pelvic floor * infections such as hpv * treatment with steroids or methotrexate * no informed consent

Keywords: pelvic organ prolapse pelvic floor dysfunction biomechanics aspiration device connective tissue
the indigo system in acute lower limb malperfusion

Conditions: Acute Ischemia of Lower Limb

Summary: to evaluate, in a controlled setting, the early safety and effectiveness of the penumbra/indigo aspiration thrombectomy systems (san francisco, california), and to define optimal technique for the use of these systems in patients with confirmed peripheral acute occlusions.


Eligibility criteria:
patients will be selected based on the investigator's assessment and evaluation of the underlying disease. the patient's medical condition should be stable, with no underlying medical condition that would prevent them from performing the required testing or from completing the study. patients should be geographically stable, willing and able to cooperate in this clinical study, and remain available for mid term follow-up. patients who do not wish to participate in this study can obtain any other standard commercially available device therapy. refusal to participate in this study will in no way affect their care at the institution. inclusion criteria * patient presenting with an acute occlusion of lower limb arteries (thrombosis no longer than 14 days) * patient presenting a score from i to iib following rutherford classification for acute limb ischemia * patient is willing to comply with specified follow-up evaluations at the specified times for the duration of the study * patient is \>18 years old * patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study * patient is eligible for treatment with the indigo system (penumbra) exclusion criteria * estimated time of intraluminal thrombus \> 14 days * patients refusing treatment * patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated * patients with a history of prior life-threatening contrast medium reaction * life expectancy of less than six months * any patient considered to be hemodynamically unstable at onset of procedure

Keywords: acute ischemia lower limb
study evaluating pantoprazole in peptic ulcer hemorrhage

Conditions: Peptic Ulcer Hemorrhage

Summary: this is a multicenter, randomized, double-blind, parallel-group, dose-ranging, comparator-controlled study of the effect of pantoprazole on intragastric ph after successful endoscopic hemostasis in hospitalized patients. patients will receive either intravenous pantoprazole (one of two regimens) or ranitidine (the comparator) within 2 hours of successful hemostasis and administration will continue for 72 hours after hemostasis.


Eligibility criteria:
inclusion criteria: * patients must be men or nonpregnant women at least 18 years of age * patients who present with a gastric or duodenal ulcer (major dimension of the ulcer must be ≥ 5 mm and ≤ 20 mm) with endoscopic appearance of spurting, oozing, or nonbleeding visible vessel (nbvv) patients presenting with adherent protruding clot are eligible if, after removal of the clot by irrigation, the underlying lesion is classified as spurting, oozing or a nbvv. patients with an actively bleeding ulcer or a nbvv within a hiatal hernia are eligible if the ulcer is located below the z-line) exclusion criteria: * patients with ulcer appearance of clean base (non-oozing, non-spurting) or flat pigmented spot; adherent clots not removed by irrigation * patients presenting with active bleeding and/or nbvv at 2 or more separate sites * patients with any severe concomitant diseases, eg, end-stage liver or renal disease, or unstable cardiovascular, pulmonary, renal, hepatic, or gastrointestinal diseases

Keywords: peptic ulcer hemorrhage
long-shaft vitrectomy probe in highly myopic eyes

Conditions: Retinal Diseases; High Myopia

Summary: this study aimed to compare the safety and efficacy of vitrectomy probe with different shaft lengths in vitreoretinal surgery of highly myopic patients. in this randomized controlled study, highly myopic patients who had axial length more than 26 mm and needed vitreoretinal surgery will be enrolled. the enrolled patients will be randomized into "30 mm shaft length group"(trial group) and "27mm shaft length group"(controlled group). we will compare the rate of wound leakage, hypotony, subconjunctival hemorrhage, probe bending, trocar removal, and endophthalmitis between the two groups. we would like to evaluate the efficacy and safety of the 30 mm shaft length vitrectomy probe.


Eligibility criteria:
inclusion criteria: * highly myopic patients (axial length \> 26mm) with vitreoretinal diseases or maculopathy requiring pars plana vitrectomy exclusion criteria: * previous history of pars plana vitrectomy * surgical plan combining encircling buckle * silicone oil or perfluorocarbon liquid use intraoperatively * previous history of pterygium surgery, trabeculectomy, glaucoma surgery * previous history of corneal, conjunctival, or scleral laceration * history of connective tissue disease

Keywords: high myopia pars plana vitrectomy vitreoretinal disease
dual trigger versus gnrha trigger combined with luteal hcg administration

Conditions: Infertility

Summary: comparing the reproductive outcomes of intracytoplasmic sperm injection (icsi) cycles in women at risk of ovarian hyperstimulation syndrome (ohss) subjected to gonadotropin releasing hormone (gnrh) antagonist protocol followed by trigger with concomitant gnrh agonist (gnrha) and low-dose human chorionic gonadotropin (hcg) administration (dual trigger), gnrha trigger with single luteal low-dose hcg or gnrha trigger with multiple luteal low-doses hcg

the gnrh antagonist fixed protocol will be used for controlled ovarian hyperstimulation (coh). transvaginal sonography (tvs) scan will be performed regularly for monitoring of the follicular growth (folliculometry). when there will be at least 3 leading follicles \> 18 mm in diameter, women will be randomized into 3 groups; group a (dual trigger group), group b (single low-dose hcg group) and group c (multiple low-doses hcg group). in group a, final oocyte maturation will be triggered by dual administration of 0.2 mg of gnrha preparation (triptorelin) sc and 1500 iu of hcg preparation im. in group b, final oocyte maturation will be triggered by administration of 0.2 mg triptorelin sc then a single im bolus of 1500 iu hcg will by administered 35-37 hours after gnrha trigger (1 hour after oocyte retrieval). in group c, final oocyte maturation will be triggered by administration of 0.2 mg triptorelin sc then 3 im boluses of 500 iu hcg will be administered day 1, day 4 and day 7 after oocyte retrieval. in all women, oocyte retrieval will be performed 34-36 hours after trigger and endometrial preparation for embryo transfer (et) will be started on the day of oocyte retrieval by giving 400 mg vaginal natural progesterone supplement once daily plus 4 mg oral estradiol valerate once daily.

Eligibility criteria:
inclusion criteria: * women subjected to icsi through controlled ovarian hyperstimulation (coh) with pituitary downregulation by gnrh antagonist. * presence of risk for development of ohss: 1) previous moderate or severe ohss; 2) pcos or polycystic ovary on ultrasound scan; 3) antral follicle count (afc) \> 14 in both ovaries; 4) basal serum amh level \> 3.36 ng/ml; 5) \> 14 follicles with diameter of ≥ 11 mm on the day of triggering of oocyte maturation; 6) e2 level \> 3000 pg/ml on the day of triggering of oocyte maturation. exclusion criteria: * age \ 35 years. * bmi \ 35 kg/m2. * moderate or severe endometriosis. * hydrosalpinx. * uterine abnormalities or myoma. * previous uterine surgery. * use of alternative techniques to minimize the risk of ohss.

Keywords: gnrha trigger luteal phase support ohss
transversus abdominal plane block at total laparoscopic hysterectomy: effect on quality of recovery

Conditions: Pain, Postoperative; Anesthesia

Summary: the transversus abdominal plane (tap) block has been used with good success to decrease postoperative pain following laparatomy. if the tap block provides any improvement in the quality of recovery following laparoscopic hysterectomy, it could decrease the need for postoperative narcotics and allow for more outpatient hysterectomy procedures.


Eligibility criteria:
inclusion criteria: * any patient undergoing laparoscopic hysterectomy * age ranges 18-80 * reading literacy * english speaking * able to give informed consent exclusion criteria: * history of relevant drug allergy * chronic opioid users who may have tolerance to pain medications * inability to understand written consent forms or give consent * age less than 18 or over 80 * any conversion to open surgery

Keywords: recovery postoperative pain laparoscopy hysterectomy ropivacaine tap block local anesthesia
speech and voice outcomes following hd-tdcs over the left sma

Conditions: Parkinson Disease

Summary: pharmaceutical and neurosurgical treatments reliably ameliorate the cardinal motor symptoms in pd but, they often yield inconsistent outcomes for speech and voice disorders, with some studies showing exacerbation of pre-treatment deficits. therefore, it is crucial to develop and optimize novel approaches that could simultaneously improve speech and voice deficits in pd and facilitate existing behavioral interventions. this project will investigate the immediate and short-term effects of multiple sessions of hd-tdcs over the left sma on speech and voice deficits in pd.

parkinson's disease (pd) is a movement disorder that affects more than one million individuals in the united states. over 90 percent of individuals with pd manifest speech and voice impairments in the course of their disease, which can significantly compromise patients' quality of life. while pharmaceutical intervention and deep brain stimulation reliably improve the cardinal motor symptoms of pd, such as tremor, rigidity, and bradykinesia, the effects of these treatments on speech and voice are inconsistent, with some studies showing the exacerbation of pre-treatment deficits. this inconsistency often occurs because treatments are calibrated to ameliorate limb motor symptoms, with no direct optimization to improve speech and voice functions. however, there is no established non-invasive neurostimulation protocol for communication disorders in pd. increasing evidence supports the application of non-invasive brain stimulation techniques such as transcranial direct current stimulation (tdcs) to improve both motor and non-motor symptoms in pd. however, limited evidence exists regarding the application of tdcs to improve speech and voice disorders in pd. moreover, there is no established long-term effect of tdcs on speech and voice deficits in pd. in this proposed study, we will address these gaps by investigating the immediate and short-term effects of high definition-transcranial direct current stimulation (hd-tdcs) over the left supplementary motor area (sma) on speech and voice deficits in 24 pd and 24 matched control participants.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of parkinson's disease * native english speakers * adequate age-relative hearing and vision to perform the outlined tasks * able to provide their own written consent exclusion criteria : * neurological disorders besides parkinson's disease * previous brain surgery including deep brain stimulation * clinical diagnosis of dementia

Keywords: brain stimulation supplementary motor area speech voice
a 14-week, multi-center study of [s,s]-reboxetine in patients with fibromyalgia.

Conditions: Fibromyalgia

Summary: this is a study to investigate the effectiveness and safety of \[s,s\]-reboxetine in relieving the symptoms of fibromyalgia in patients. a previous study demonstrated clinically meaningful treatment effects in fibromyalgia, based on pain and functional endpoints.


Eligibility criteria:
inclusion criteria: * male or female of any race, at least 18 years of age * patients must meet the acr criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites) exclusion criteria: * patients with other severe pain (eg, diabetic peripheral neuropathy and postherpetic neuralgia) that may confound assessment or self evaluation of the pain associated with fibromyalgia * patients with any autoimmune rheumatic disorder, non-focal rheumatic disease (other than fibromyalgia), active infection, or untreated endocrine disorder * a current or recent diagnosis (last 6 months) or episode of major depressive disorder, dysthymia and/or uncontrolled depression * history of mania, hypomania, other psychotic disorder, or current mood disorder with psychotic features

Keywords: phase 3, safety and efficacy study, [s,s[-reboxetine, fibromyalgia
feasibility of radiofrequency resection in oropharyngeal tumor surgery

Conditions: Radiofrequency Resection

Summary: in the last years radiofrequency resection has become a frequent method in surgical subspecialties. although many departments are using this method for the resection of tumor in the oropharynx, there is no study so far which describes feasibility and safety. goal of this study is to show feasibility and safety of radiofrequency resection in oropharyngeal tumor surgery.

in the last years radiofrequency resection has become a frequent method in surgical subspecialties. although many departments are using this method for the resection of tumor in the oropharynx, there is no study so far which describes feasibility and safety. goal of this study is to show feasibility and safety of radiofrequency resection in oropharyngeal tumor surgery.

Eligibility criteria:
inclusion criteria: - 18 years and older benign or malign tumor of the oropharynx tumor must be resectable transorally exclusion criteria: * prior radiotherapy or chemotherapy
transcriptomic study of ibd-associated colorectal cancer

Conditions: Colorectal Cancer, Genetics of

Summary: chronic inflammatory bowel disease (ibd) is associated with an increased risk of colorectal cancer (crc) in historical cohorts. the pathways of oncogenesis of these crcs, which are very different clinically from de novo crcs, are currently unknown. the aim of our work is to identify specific molecular signatures of crc occurring in the setting of ibd.


Eligibility criteria:
inclusion criteria: * person 18 years of age or older * person with colorectal cancer in the context of ibd * person who has received complete information on the organization of the research and who has signed an informed consent * person affiliated to a social security plan or beneficiary of such a plan. exclusion criteria: * person referred to in articles l. 1121-5, l. 1121-7 and l1121-8 of the public health code: * pregnant woman, parturient or nursing mother * minor (not emancipated) * adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice) * person of legal age who is unable to express his or her consent * person deprived of liberty by a judicial or administrative decision, persons subject to psychiatric care under articles l. 3212-1 and l. 3213-1.

Keywords: inflammatory bowel disease